Clinical trials: Metastatic Neoplasm
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Hormone-refractory Prostate Cancer
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
Prostate cancer is the most common non-skin tumor diagnosed in men and the second leading cause of cancer death in men in Western countries.
- Trial name
- PREMIERE (NCT02288936)
- Testing
- Enzalutamide
- Where
- 16 sites in Spain
- Volunteers
- 98 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
68Ga-FAPI PET/CT, Metastatic Adenoid Cystic Carcinoma
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
- Trial name
- NCT05499936
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Melanoma
Evaluation of Hypoxia in Primary Melanoma
When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS.
- Trial name
- NCT06831071
- Testing
- Pimonidazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yana Najjar
Non-small Cell Lung Cancer, Quality of Life
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
- Conditions
- Non-small Cell Lung Cancer, Quality of Life, Brain Metastases, Venous Thromboembolism
- Trial name
- NCT03870464
- Testing
- CT-scans extended, MRI scan of the brain, Prospective registration of irAEs
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- University of Southern Denmark
Urothelial Cancer
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy…
- Trial name
- CheckMate901 (NCT03036098)
- Testing
- Nivolumab, Ipilimumab, Gemcitabine
- Where
- 174 sites in United States, Argentina and 28 more
- Volunteers
- 1,314 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
NSCLC
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study
Outcome for patients diagnosed with advanced lung cancer remains poor; alternative treatment options are urgently needed. Studies in other metastatic cancers indicate radiotherapy to the primary tumour can improve outcomes.
- Trial name
- PRIME_LUNG (NCT05222087)
- Testing
- Radiotherapy, SoC systemic therapy
- Where
- 6 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002752
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Metastatic Breast Cancer
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic signature or BRCA 1 or 2 somatic mutation…
- Trial name
- RUBY (NCT02505048)
- Testing
- rucaparib
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- UNICANCER
HR+HER2- Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after…
- Trial name
- NCT06343948
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Cancer Stage IV, Peritoneal Metastasis
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
The goal of this clinical trial is to evaluate the impact of conversion surgery on overall survival (OS) in patients with gastric cancer peritoneal metastases (GCPM) who show a good response to preoperative systemic therapy…
- Trial name
- CONVERGENCE (NCT07241715)
- Testing
- Conversion Surgery, Systemic Therapy/Standard of Care
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Metastatic Breast Cancer
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01421017
- Testing
- Radiation, Imiquimod, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Indeterminate Pulmonary Nodules, Lung Metastases
AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.
- Conditions
- Indeterminate Pulmonary Nodules, Lung Metastases, Second Primary Cancer, Lung Cancer
- Trial name
- AI-SONAR (NCT05375591)
- Testing
- Non-Interventional Study
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Screening Tool, Focus Group
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the…
- Trial name
- ACCESS (NCT06412874)
- Testing
- Screening tool
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Recurrent Melanoma, Stage IV Skin Melanoma
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
This randomized phase II trial is studying how well giving vaccine therapy together with or without recombinant interleukin-12 followed by daclizumab works in treating patients with melanoma that has spread to other places in the…
- Trial name
- NCT01307618
- Testing
- NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma
Naltrexone and Propranolol Combined With Immunotherapy
Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral…
- Trial name
- NCT05968690
- Testing
- Propranolol, Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sarah Weiss
Metastatic Cancer
Electronic Patient Reporting of Symptoms During Cancer Treatment
The current study is designed to test nationally whether patients' outcomes and utilization of services can be improved through symptom monitoring via patient-reported outcomes between visits.
- Trial name
- PRO-TECT (NCT03249090)
- Testing
- Patient Self-Reporting of Symptoms, Usual Care Delivery
- Where
- 45 sites in United States
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Alliance Foundation Trials, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.